Clinical Trial Details

< Previous Trial     Next Trial >
Study ID P10-3
Investigator
Candice McCoy, MD,   Dendreon
Title A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Conditions Advanced Prostate Cancer
Prostatic Neoplasms
Interventions Biological: sipuleucel-T
Phase N/A
Purpose The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Male
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • subjects must be at least 18 years of age
  • subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
  • subjects must understand and sign an informed consent form Exclusion Criteria:
  • none
  • Study Location
    21st Century Oncology
    Scottsdale, Arizona, 85251
    Contact N/A

    Information objtained from ClinicalTrials.gov, on 10/25/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
    Please refer to this study by its ClinicalTrials.gov identifier: NCT01306890


    Back to Search Results